E. Garry Menzel - Feb 28, 2022 Form 4 Insider Report for TCR2 THERAPEUTICS INC. (TCRR)

Role
President & CEO, Director
Signature
Margaret Siegel as Attorney-In-Fact
Stock symbol
TCRR
Transactions as of
Feb 28, 2022
Transactions value $
$3,278
Form type
4
Date filed
3/18/2022, 04:24 PM
Previous filing
Dec 10, 2021
Next filing
Jun 8, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TCRR Common Stock Award $3.28K +1.43K +0.79% $2.30 181K Feb 28, 2022 Direct F2, F3
holding TCRR Common Stock 84.5K Feb 28, 2022 See Footnote F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Consists of 84,527 shares of common stock held by Dr. Garry Menzel, as Trustee of the Garry E. Menzel and Mary E. Henshall Family Trust, under instrument of trust dated July 29, 2010. Dr. Menzel is the trustee of the Garry E. Menzel and Mary E. Henshall Family Trust and may be deemed to beneficially own these securities.
F2 The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the issuer's 2018 Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of September 1, 2021 through February 28, 2022. This transaction is exempt under Rule 16b-3(c).
F3 In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on February 28, 2022.